← Every company
Alnylam Pharmaceuticals Inc Patents
What Alnylam Pharmaceuticals Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
ALNY on carbonthat →Filings on file
56
Granted
0
Still pending
56
Filed under
2 names
56 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFC12N 15/1136, A61P 3/06, A61K 31/7088, A61K 48/00, C12N2310/14, C12N2310/3125, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/344, C12N2310/346, C12N2310/351Filed as Alnylam Pharmaceuticals, Inc.2026-04-06Lucas D. BonDurant | pending |
| METHODS AND COMPOSITIONS FOR TREATING TRANSTHYRETIN (TTR)- ASSOCIATED DISEASESFiled as ALNYLAM PHARMACEUTICALS, INC.2026-02-23XIUQING GAO | pending |
| Aminoadipate-Semialdehyde Synthase (AASS) iRNA Compositions and Methods of Use ThereofFiled as ALNYLAM PHARMACEUTICALS, INC.2026-02-03LEILA NOETZLI | pending |
| METHODS AND COMPOSITIONS FOR TREATING CTNNB1-ASSOCIATED DISORDERSA61K 31/7115, A61K 31/713, C12N 15/113, A61P 35/04, A61P 35/00, A61K 39/3955, A61K2039/505, A61K2039/54, A61K2039/545, C12N2310/14, C12N2310/312, C12N2310/315, C12N2310/3183, C12N2310/319, C12N2310/321, C12N2310/322, C12N2320/11, C12N2320/31, C12N2320/32, C12N2320/35, C12N2310/344, C12N2310/3521, C12N2310/3533Filed as Alnylam Pharmaceuticals, Inc.2026-02-03Gloria Lau | pending |
| PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFA61K 31/7125, A61P 43/00, A61P 1/16, A61P 3/06, C07H 19/067, C07H 19/167, C07H 21/02, C12N 15/113, C12N 15/1137, C12N2310/14, C12N2310/321, C12N2310/322, C12N2310/3515, C12P 19/34, C12N2310/3521, C12N2310/3533Filed as Alnylam Pharmaceuticals, Inc.2026-01-23Kevin Fitzgerald | pending |
| TRANSMEMBRANE SERINE PROTEASE 2 (TMPRSS2) IRNA COMPOSITIONS AND METHODS OF USE THEREOFC12N 15/1137, C12N 15/1138, C12N 15/1062, C12N2310/14, C12N2310/312, C12N2310/315, C12N2310/343, C12N2310/3515, C12N2320/11, C12Y 304/21, C12N2310/321, C12N2310/3527, C12N2310/3521Filed as Alnylam Pharmaceuticals, Inc.2026-01-13Akin Akinc | pending |
| ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFC12N 15/1136, A61P 3/06, A61K 31/7088, A61K 48/00, C12N2310/14, C12N2310/3125, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/344, C12N2310/346, C12N2310/351Filed as Alnylam Pharmaceuticals, Inc.2026-01-09Lucas D. BonDurant | pending |
| APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFC12N 15/113, A61P 3/00, A61K 31/713, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/351, C12N2310/3521, C12N2310/3533Filed as Alnylam Pharmaceuticals, Inc.2025-12-08Frederic Tremblay | pending |
| COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) GENESC12N 15/113, A61P 43/00, A61P 1/16, A61P 3/06, A61K 31/713, C12N 15/1137, C12N2310/14, C12N2310/314, C12N2310/315, C12N2310/321, C12N2310/344, C12N2310/3515, C12N2310/3521Filed as Alnylam Pharmaceuticals, Inc.2025-12-08Brian Bettencourt | pending |
| 5’-MODIFIED MONOMERS, OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNASFiled as ALNYLAM PHARMACEUTICALS, INC.2025-12-05Dhrubajyoti DATTA | pending |
| CD81 IRNA COMPOSITIONS AND METHODS OF USE THEREOFFiled as ALNYLAM PHARMACEUTICALS, INC.2025-12-04PATRICK HASLETT | pending |
| COMPOSITIONS AND METHODS FOR SILENCING UGT1A1 GENE EXPRESSIONC12N 15/1137, C12N 5/067, C12N2310/14, C12N2310/3125, C12N2310/315, C12Y 204/01017Filed as ALNYLAM PHARMACEUTICALS, INC.2025-11-19DONALD FOSTER | pending |
| COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENEC12N 15/1136, A61P 1/16, A61P 13/12, A61K 31/713, C12N2310/14, C12N2310/315, C12N2310/322, C12N2310/351, C12N2320/11, C12N2310/3533Filed as ALNYLAM PHARMACEUTICALS, INC.2025-11-14HO-CHOU TU | pending |
| SINGLE-STRANDED LOOP OLIGONUCLEOTIDESC12N 15/113, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/351, C12N2310/531Filed as ALNYLAM PHARMACEUTICALS, INC.2025-11-11Muthiah MANOHARAN | pending |
| COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)C12N 15/113, A61P 25/28, C12N2310/11, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/351Filed as Alnylam Pharmaceuticals, Inc.2025-11-10Anna Borodovsky | pending |
| SOLUTE CARRIER FAMILY MEMBER IRNA COMPOSITIONS AND METHODS OF USE THEREOFC12N 15/1138, C12N2310/14, C12N2310/351Filed as Alnylam Pharmaceuticals, Inc.2025-11-06Lucas D. Ward | pending |
| ANGIOPOIETIN-LIKE 3 (ANGPTL3) IRNA COMPOSITIONS AND METHODS OF USE THEREOFC12N 15/113, C12N 15/1136, A61K 47/549, A61P 3/06, A61K 31/713, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/34, C12N2310/344, C12N2310/346, C12N2310/351, C12N2310/3515, C12N2310/3521, C12N2310/3533, C12N2320/32, C12N2320/35, C12N2320/51Filed as Alnylam Pharmaceuticals, Inc.2025-11-06William Querbes | pending |
| MODIFIED OLIGONUCLEOTIDESC12N 15/111, A61K 31/713, C12N 15/113, C12N2310/323, C12N2310/344, C12N2320/51, C12N2310/322, C12N2310/3533, C12N2310/321, C12N2310/3521Filed as Alnylam Pharmaceuticals, Inc.2025-11-04Muthiah MANOHARAN | pending |
| SIRNAS TARGETING COMPLEMENT FACTOR H-RELATED (CFHR) GENE TRANSCRIPTS AND METHODS OF USEFiled as ALNYLAM PHARMACEUTICALS, INC.2025-11-04SIMINA TICAU | pending |
| siRNAs Targeting Complement Factor H-Related (CFHR) Gene Transcripts and Methods of UseFiled as ALNYLAM PHARMACEUTICALS, INC.2025-10-28SIMINA TICAU | pending |
| Mivelsiran Compositions and Methods of Use ThereofA61P 25/28, A61K 31/713, C12N 15/113, A61K 9/0019, A61K 9/08, C12N2310/14, C12N2310/312, C12N2310/3125, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/3521, C12N2310/3533Filed as ALNYLAM PHARMACEUTICALS, INC.2025-10-24BRET LEE BOSTWICK | pending |
| MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) IRNA FORMULATIONS AND METHODS OF USE THEREOFFiled as ALNYLAM PHARMACEUTICALS, INC.2025-10-15ANDY PHUNG | pending |
| SNCA IRNA FORMULATIONS AND METHODS OF USE THEREOFFiled as ALNYLAM PHARMACEUTICALS, INC.2025-10-15ANDY PHUNG | pending |
| EXTRAHEPATIC DELIVERY OF DOUBLE-STRANDED RNA AGENTSA61K 47/542, A61K 31/713, C12N 15/113, A61P 25/28, C12N 15/111, C12N2310/14, C12N2310/3515, C12N2320/32Filed as ALNYLAM PHARMACEUTICALS, INC.2025-10-10Jayaprakash K. NAIR | pending |
| Formulations for Oligonucleotide DeliveryA61P 25/28, A61K 31/713, A61K 47/542, A61K 9/0019, A61K 9/0085, A61K 45/06, A61K 47/02, C12N 15/113, C12N2310/14, C12N2310/312, C12N2310/315, C12N2310/317, C12N2310/322, C12N2310/3515, C12N2310/321, C12N2310/3521, C12N2310/3533Filed as ALNYLAM PHARMACEUTICALS, INC.2025-10-09ANDY PHUNG | pending |
| COMPLEMENT COMPONENT C3 iRNA COMPOSITIONS AND METHODS OF USE THEREOFC12N 15/113, A61K 31/7115, C12N2310/14, C12N2310/3125, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/3235, C12N2310/351Filed as Alnylam Pharmaceuticals, Inc.2025-09-25Gregory Hinkle | pending |
| PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USE THEREOFFiled as ALNYLAM PHARMACEUTICALS, INC.2025-09-18JOHN GANSNER | pending |
| COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOFC12N 15/113, A61K 47/549, A61P 7/02, A61K 9/0019, A61K 31/7088, A61K 45/06, A61K 48/00, C12N2310/11, C12N2310/14, C12N2310/3125, C12N2310/313, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/343, C12N2310/346, C12N2310/3521, C12N2310/3533Filed as Alnylam Pharmaceuticals, Inc.2025-09-09Mark Keating | pending |
| PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOFC12N 15/1137, A61K 47/549, A61P 43/00, A61P 3/06, A61K 31/713, C12N2310/14, C12N2310/312, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/343, C12N2310/351, C12N2310/3515, C12N2310/3533, C12N2320/35, C12Y 304/21Filed as Alnylam Pharmaceuticals, Inc.2025-08-26Anna Borodovsky | pending |
| METHODS AND COMPOSITIONS FOR TREATING AN ANGIOTENSINOGEN- (AGT-) ASSOCIATED DISORDERFiled as ALNYLAM PHARMACEUTICALS, INC.2025-08-25NITENDER GOYAL | pending |
| PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USE THEREOFC12N 15/1137, C12Y 304/21007, C12N 15/113, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/346, C12N2310/351, C12N2310/3515Filed as ALNYLAM PHARMACEUTICALS, INC.2025-08-07MARTINA SLINGSBY | pending |
| REVERSIR MOLECULES AND METHODS OF USE THEREOFA61K 31/7125, C12N 15/111, C12N 15/113, C12N 15/1136, A61K 45/06, C12N2310/113, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/3231, C12N2310/3341, C12N2310/351, C12N2310/344, C12N2310/3521, C12N2310/322, C12N2310/3533, A61K2300/00Filed as Alnylam Pharmaceuticals, Inc.2025-07-28Ivan Zlatev | pending |
| SIX MEMBERED RING CONTAINING OLIGOMERSFiled as ALNYLAM PHARMACEUTICALS, INC.2025-07-24Muthiah MANOHARAN | pending |
| POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOFC12N 15/1138, A61K 47/549, A61P 31/06, G01N 33/575, A61K 9/0019, A61K 9/08, A61K 9/1271, A61K 9/5123, A61K 31/7088, A61K 31/712, A61K 31/7125, A61K 45/06, A61K 47/02, A61K 47/28, C12N2310/11, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/3341, C12N2310/341, C12N2310/346, C12N2310/351, C12N2310/3515, C12N2320/35, G01N 33/56983, C12N2310/3521Filed as Alnylam Pharmaceuticals, Inc.2025-07-18Gregory Hinkle | pending |
| KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOFC12N 15/1137, A61K 47/549, A61P 1/16, A61P 3/06, A61P 3/10, A61P 13/12, A61K 31/713, A61K 47/02, C12N2310/14, C12N2310/3125, C12N2310/314, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/346, C12N2310/351, C12N2310/53, C12Y 207/01003Filed as Alnylam Pharmaceuticals, Inc.2025-06-27Leila Noetzli | pending |
| TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASESC12N 15/113, C12N2310/11, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/344, C12N2310/346, C12N2310/3515, C12N2320/34Filed as Alnylam Pharmaceuticals, Inc.2025-06-24Jayaprakash K. Nair | pending |
| INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERYFiled as ALNYLAM PHARMACEUTICALS, INC.2025-06-20JOE PANARESE | pending |
| 5'-MODIFIED MONOMERS, OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNASFiled as ALNYLAM PHARMACEUTICALS, INC.2025-06-13JUAN SALINAS | pending |
| 5'-MODIFIED MONOMERS, OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNASFiled as ALNYLAM PHARMACEUTICALS, INC.2025-06-13JUAN SALINAS | pending |
| ALPHA-V BETA-6 (avb6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERYA61K 47/545, A61K 47/55, A61P 25/28, A61K 9/0019, A61K 9/0043, A61K 9/007, C07D 401/14, C07D 403/14, C07D 471/04, C07D 487/04, C07H 21/02, C12N 15/113, C12N2310/14, C12N2310/312, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/343, C12N2310/344, C12N2310/346, C12N2310/351, C12N2310/3521, C12N2310/3533, C12N2320/32Filed as Alnylam Pharmaceuticals, Inc.2025-06-12Jayaprakash K. Nair | pending |
| COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOFC12N 15/113, A61K 31/713, C12N 15/66, C12N2310/14, C12N2310/3125, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/343, C12N2310/351, C12N2310/3521, C12N2310/3533Filed as Alnylam Pharmaceuticals, Inc.2025-06-12Mark Keating | pending |
| DUAL CONJUGATE COMPOUNDS FOR EXTRAHEPATIC DELIVERYFiled as ALNYLAM PHARMACEUTICALS, INC.2025-06-11JAYAPRAKASH K. NAIR | pending |
| DYSTROPHY MYOTONIC PROTEIN KINASE (DMPK) IRNA COMPOSITIONS AND METHODS OF USE THEREOFFiled as ALNYLAM PHARMACEUTICALS, INC.2025-06-11KARYN SCHMIDT | pending |
| SOLUTE CARRIER FAMILY 27 MEMBER 5 (SLC27A5) IRNA COMPOSITIONS AND METHODS OF USE THEREOFFiled as ALNYLAM PHARMACEUTICALS, INC.2025-05-28BENJAMIN P. GARFINKEL | pending |
| METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDERA61K 31/7115, A61K 31/713, C12N 15/1137, A61K 47/549, A61P 3/06, A61K 9/0019, A61K 39/3955, A61K 45/06, A61K2039/505, A61K2039/545, A61K2300/00, C07K 16/40, C12N2310/14, C12N2310/315, C12N2310/321, C12Y 304/21061Filed as Alnylam Pharmaceuticals, Inc.2025-05-21Kevin Fitzgerald | pending |
| FACTOR XII (HAGEMAN FACTOR) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), AND KININOGEN 1 (KNG1) IRNA COMPOSITIONS AND METHODS OF USE THEREOFA61K 31/713, C12N 15/113, C12N 15/1137, A61K 47/549, A61P 7/10, A61P 7/02, A61P 9/10, A61P 43/00, A61P 9/00, A61P 9/12, A61K 45/06, C12N2310/14, C12N2310/31, C12N2310/321, C12N2310/322, C12N2310/344, C12N2310/3521, C12N2310/3533, C12Q 1/6883Filed as Alnylam Pharmaceuticals, Inc.2025-05-19Akin Akinc | pending |
| METHOD FOR SEPARATING OLIGONUCLEOTIDESFiled as ALNYLAM PHARMACEUTICALS, INC.2025-04-30JOSHUA BROOKS | pending |
| COMPOSITIONS AND METHODS FOR TREATING TRANSTHYRETIN (TTR) MEDIATED AMYLOIDOSISA61K 31/7105, A61K 48/00, C12N 15/113, A61P 25/28, A61P 9/00, A61P 25/00, A61K 9/0019, A61K 9/08, A61K 9/1075, A61K 31/07, A61K 31/135, A61K 31/138, A61K 31/167, A61K 31/194, A61K 31/341, A61K 31/423, A61K 31/426, A61K 31/445, A61K 31/495, A61K 31/496, A61K 31/573, A61K 31/603, A61K 31/713, A61K2300/00, C12N2310/14, C12N2310/321, C12N2310/344, C12N2310/3521, C12N2320/31, C12N2320/35Filed as Alnylam Pharmaceuticals, Inc.2025-04-17Jared A. Gollob | pending |
| METHODS AND COMPOSITIONS FOR TREATING TRANSTHYRETIN (TTR)- ASSOCIATED DISEASESFiled as Alnylam Pharmaceuticals, Inc.2025-04-08Xiuqing Gao | pending |
| PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USE THEREOFC12N 15/1137, A61P 7/04, A61K 9/0019, A61K 31/712, A61K 31/7125, A61K 31/713, A61K 47/02, C12N2310/11, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/351, C12Y 304/21007Filed as ALNYLAM PHARMACEUTICALS, INC.2025-04-04MARTINA SLINGSBY | pending |
| METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12)C12N 15/113, A61P 9/00, C12N2310/11, C12N2310/14, C12N2310/315, C12N2310/344, C12N2310/346, C12N2310/351, C12N2310/322, C12N2310/3533Filed as Alnylam Pharmaceuticals, Inc.2025-04-04James Butler | pending |
| PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USE THEREOFFiled as ALNYLAM PHARMACEUTICALS, INC.2025-04-03JOHN GANSNER | pending |
| MODIFIED DOUBLE-STRANDED RNA AGENTSC12N 15/111, C12N 15/113, C12N2310/14, C12N2310/313, C12N2310/315, C12N2310/321, C12N2310/33, C12N2310/344, C12N2310/351, C12N2310/3515, C12N2320/32, C12N2330/30, C12N2310/32, C12N2310/31, C12N2310/3521, C12N2310/322, C12N2310/3533Filed as ALNYLAM PHARMACEUTICALS, INC.2025-03-27Muthiah MANOHARAN | pending |
| MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNASC12N 15/111, C12N 15/113, A61K 9/0019, A61K 31/7105, A61K 31/7115, A61K 31/712, A61K 31/7125, A61K 31/713, C12N2310/14, C12N2310/315, C12N2310/32, C12N2310/321, C12N2310/322, C12N2310/3231, C12N2310/3233, C12N2310/33, C12N2310/344, C12N2310/351, C12N2320/53, C12N2310/3521Filed as ALNYLAM PHARMACEUTICALS, INC.2025-03-26Muthiah MANOHARAN | pending |
| METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDERFiled as Alnylam Pharmaceuticals, Inc.2025-03-25Kevin Fitzgerald | pending |
| IRNA COMPOSITIONS AND METHODS FOR SILENCING GROWTH FACTOR RECEPTOR BOUND PROTEIN 14 (GRB14) IN THE LIVERFiled as ALNYLAM PHARMACEUTICALS, INC.2025-03-21LUCAS BONDURANT | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on ALNY
Company overviewEverything on ALNY in one place, with the price.SEC filingsWhat ALNY's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat ALNY's own officers and directors buy and sell.Executive payWhat ALNY awarded its chief executive, and what it became.Who owns itEvery manager reporting a position in ALNY.Funds holding itWhich funds and ETFs hold ALNY, and how big a bet.LobbyingWhat ALNY spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on ALNY's account, and who they worked for.